CINECA IRIS Institutional Research Information System

MATRONE, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.892
EU - Europa 2.936
AS - Asia 860
AF - Africa 245
SA - Sud America 25
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 3
Totale 7.968
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.811
IT - Italia 864
DE - Germania 723
SE - Svezia 545
CN - Cina 328
SG - Singapore 235
AT - Austria 218
BG - Bulgaria 217
GB - Regno Unito 205
CI - Costa d'Avorio 163
IN - India 90
VN - Vietnam 78
SN - Senegal 71
CA - Canada 66
RU - Federazione Russa 40
HK - Hong Kong 37
TR - Turchia 35
CZ - Repubblica Ceca 20
FI - Finlandia 17
PL - Polonia 15
FR - Francia 13
JP - Giappone 12
GR - Grecia 11
KR - Corea 11
UA - Ucraina 10
NL - Olanda 9
ID - Indonesia 8
AU - Australia 7
CL - Cile 7
MX - Messico 7
CR - Costa Rica 6
BR - Brasile 5
IR - Iran 5
MG - Madagascar 5
CH - Svizzera 4
ES - Italia 4
HU - Ungheria 4
IE - Irlanda 4
PH - Filippine 4
AR - Argentina 3
BE - Belgio 3
CY - Cipro 3
EC - Ecuador 3
EG - Egitto 3
IL - Israele 3
PK - Pakistan 3
TW - Taiwan 3
AZ - Azerbaigian 2
BH - Bahrain 2
DK - Danimarca 2
EU - Europa 2
NG - Nigeria 2
RS - Serbia 2
SV - El Salvador 2
UY - Uruguay 2
VE - Venezuela 2
A1 - Anonimo 1
BY - Bielorussia 1
CO - Colombia 1
EE - Estonia 1
GE - Georgia 1
MT - Malta 1
PE - Perù 1
PT - Portogallo 1
PY - Paraguay 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
ZA - Sudafrica 1
Totale 7.968
Salva come PNG Salva come JPEG
Città #
Chandler 569
Fairfield 411
Ashburn 294
Milan 256
Houston 235
Woodbridge 223
Sofia 216
Vienna 205
New York 192
Seattle 171
Abidjan 163
Wilmington 147
Cambridge 132
Princeton 127
Ann Arbor 126
Beijing 116
Florence 101
Lawrence 95
Boulder 82
Dakar 71
Serra 70
Singapore 70
Medford 66
Pisa 65
London 60
Frankfurt am Main 59
Ottawa 52
Dong Ket 42
Des Moines 39
Rome 39
Bremen 35
Redwood City 35
Dearborn 33
San Diego 31
Redmond 28
Hong Kong 25
Munich 22
Nanjing 22
Washington 22
Shanghai 20
Brno 18
Ogden 18
Vicopisano 16
Izmir 15
Lancaster 14
Los Angeles 14
Bengaluru 13
Hyderabad 13
Jiaxing 12
Scandicci 12
Norwalk 11
Chiesina Uzzanese 10
Hangzhou 10
Chengdu 9
Shenyang 9
Guangzhou 8
Istanbul 8
Nanchang 8
Changsha 7
Hefei 7
Tianjin 7
Boston 6
Hebei 6
Jinan 6
Montreal 6
Phoenix 6
Pontedera 6
San José 6
Tokyo 6
Toronto 6
Antananarivo 5
Buffalo 5
Kunming 5
Livorno 5
Mumbai 5
Ningbo 5
Salt Lake City 5
Samsun 5
Santiago 5
Ulan-ude 5
Wuhan 5
Amsterdam 4
Bari 4
Berlin 4
Cascina 4
Chongqing 4
Dallas 4
Dublin 4
Duncan 4
Jakarta 4
Moscow 4
Naples 4
Napoli 4
Parma 4
Pune 4
Seoul 4
Thessaloníki 4
Thrissur 4
Atakum 3
Brussels 3
Totale 5.189
Salva come PNG Salva come JPEG
Nome #
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 178
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 161
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 152
Targeted Therapy in Thyroid Cancer: State of the Art 151
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 147
null 146
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 146
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 145
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 142
A patient with MEN1 and end‑stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation 134
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 134
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 133
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 132
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 123
Il carcinoma tiroideo: nuove prospettive terapeutiche. 120
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 117
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 115
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 114
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 111
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 111
Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer 111
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 110
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 110
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 108
null 107
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 107
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 103
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 102
Central Neck Dissection Cannot Be Avoided In Medullary Thyroid Cancer (MTC) On The Basis Of Presurgical Serum Calcitonin (CT) 101
The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy 101
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 98
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 94
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 91
Potential impact of BMI on the aggressiveness of presentation and clinical outcome of Differentiated Thyroid Cancer 91
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 90
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 87
null 86
MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis? 86
Decreased serum vascular endothelial growth factor-D levels in metastatic patients with differentiated thyroid carcinoma 86
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 85
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 85
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 83
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 83
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 82
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 82
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 81
Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism 81
Cabozantinib: An orphan drug for thyroid cancer 81
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 81
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 81
SAT-393 Cognitive Function Evaluation in an Italian Cohort of Patients with Post-Operative Hypoparathyroidism 80
Increased Risk of Renal Complications in Patients with Chronic Postsurgical Hypoparathyroidism Treated with Conventional Therapy 78
Response to letter: "postoperative thyroglobulin and neck ultrasound in the risk restratification and decision to perform131i ablation" 72
A Patient with Advanced Medullary Thyroid Cancer and Progressive Symptomatic Distant Metastases: When to Start Systemic Therapy 72
Expression of duox1 in papillary thyroid cancer and in normal thyroid tissues and correlation with ret/ptc rearrangements 72
null 70
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 70
After 20 Years, RET genetic screening still identifies new germline and somatic mutations 69
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 68
Predictors Of Vandetanib Response In The Locally Advanced Or Metastatic Medullary Thyroid Cancer: A Single Center Experience 67
Un caso di MEN2B con anomalie scheletriche multiple 67
Clinical–Pathological Features and Treatment Outcome of Patients With Hobnail Variant Papillary Thyroid Carcinoma 67
Differentiated Thyroid Cancer, From Active Surveillance to Advanced Therapy: Toward a Personalized Medicine 66
RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency 62
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 62
Role Of Prophylactic Central Compartment Lymph Node Dissection On The Outcome Of Patients With Papillary Thyroid Carcinoma And Synchronous Ipsilateral Cervical Lymph Node Metastases 59
Impact of energy-based devices in pediatric thyroid surgery 58
First report of benign track seeding after robot-assisted transaxillary thyroid surgery 57
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 57
Clinical-Pathological and Molecular Evaluation of 451 NIFTP Patients from a Single Referral Center 56
Pre- And Post-Operative Circulating Tumoral Dna In Patients With Medullary Thyroid Carcinoma 56
La scintigrafia con 99mTecnezio-metossi-isobutil-isonitrile è una metodica utile per caratterizzare il rischio di malignità nei noduli tiroidei a citologia indeterminata 55
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 54
Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism 53
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 51
Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase? 50
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 48
Systemic treatment of advanced, metastatic, medullary thyroid carcinoma 47
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 44
Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses 44
Management and follow-up of differentiated thyroid cancer not submitted to radioiodine treatment: a systematic review 43
Risk factors for renal calcifications and determinants of hypercalciuria in patients with chronic, post-surgical hypoparathyroidism 43
Obesity as a risk factor for thyroid cancer 42
MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients 42
Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer 41
Ultrasound features and risk stratification systems to identify medullary thyroid carcinoma 40
Renal complications and quality of life in postsurgical hypoparathyroidism: a case–control study 40
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer 38
Poorly differentiated and anaplastic thyroid cancer: Insights into genomics, microenvironment and new drugs 38
Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: a case report 38
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 35
Il carcinoma della tiroide 33
Correction to: Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer (Journal of Endocrinological Investigation, (2021), 44, 10, (2139-2151), 10.1007/s40618-020-01491-3) 33
Thyroid carcinomas 29
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine 29
Higher RET gene expression levels do not represent an alternative RET activation mechanism in medullary thyroid carcinoma 28
Pre-surgical Value Of Basal Calcitonin Is Not Predictive Of Central Neck Compartment Metastases. 27
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 26
Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib 25
Ret Oncogene and Thyroid Carcinoma 21
Totale 8.008
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.379
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.379
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.500 141 92 116 81 126 167 158 98 113 143 233 32
2020/2021749 80 40 83 23 42 88 78 43 60 40 63 109
2021/20221.061 35 32 29 52 208 142 47 42 56 50 74 294
2022/20232.204 239 320 191 166 207 228 44 161 451 17 155 25
2023/20241.472 108 143 196 118 190 273 85 35 26 23 109 166
2024/202521 21 0 0 0 0 0 0 0 0 0 0 0
Totale 8.232